FINANCIAL barriers to asthma medications continue to compromise patient outcomes, increasing the risk of asthma attacks and emergency room visits, according to a recent analysis spanning 2011 to 2022.
A new study has revealed that cost-related medication non-adherence (CRN) affects approximately one in six U.S. adults with asthma, despite a declining trend in the last decade. The research, which analyzed data from the National Health Interview Survey, included 30,793 participants, representing 8.1% (19.38 million) of the U.S. population.
While asthma is among the most common chronic conditions, untreated cases due to cost barriers significantly heighten the burden on individuals and healthcare systems. Adults with asthma who reported CRN were nearly twice as likely to suffer asthma attacks (adjusted OR 1.95, 95% CI 1.78–2.13) and were at a 63% greater risk of emergency room visits (adjusted OR 1.63, 95% CI 1.44–1.84).
Who is Affected by CRN?
The study identified multiple factors influencing CRN, including demographic disparities and comorbidities. Those most affected often belong to populations already vulnerable to financial hardship, highlighting inequities in healthcare accessibility.
Trends and Implications
From 2011 to 2022, CRN prevalence declined overall, suggesting possible improvements in healthcare access or affordability. However, with one in six adults still unable to afford essential medications, significant gaps remain.
The findings underscore the pressing need for policies that mitigate medication costs and improve access to care. Social support programs, insurance reform, and patient-centered interventions could play crucial roles in addressing this public health challenge.
Reference: Hung CT et al. Cost-related non-adherence to medications among adults with asthma in the USA, 2011–2022. Thorax 2025;80:16-23.
Anaya Malik | AMJ
